Octagon Capital Advisors LP grew its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 128.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,450,000 shares of the company's stock after purchasing an additional 5,877,778 shares during the quarter. Taysha Gene Therapies makes up approximately 3.0% of Octagon Capital Advisors LP's portfolio, making the stock its 12th largest holding. Octagon Capital Advisors LP owned 5.10% of Taysha Gene Therapies worth $18,078,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ground Swell Capital LLC bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $25,000. Cibc World Markets Corp bought a new position in Taysha Gene Therapies during the fourth quarter valued at about $28,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies during the 4th quarter valued at approximately $31,000. Hsbc Holdings PLC grew its holdings in shares of Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after purchasing an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $39,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on TSHA. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $6.63.
Check Out Our Latest Stock Report on TSHA
Taysha Gene Therapies Stock Performance
TSHA stock opened at $2.32 on Tuesday. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $4.32. The business has a 50 day moving average of $1.66 and a 200-day moving average of $1.81. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a market cap of $475.73 million, a PE ratio of 3.68 and a beta of 0.90.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.
Taysha Gene Therapies Profile
(
Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading
Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
